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The ability of the CD300a inhibitory receptor to modulate immune cell functions and its 
involvement in the pathogenesis of many diseases has aroused a great interest in this 
molecule. Within human CD4+ T lymphocytes from healthy donors, the inhibitory receptor 
CD300a is differentially expressed among different T helper subsets. However, there are 
no data about the expression and regulation of CD300a receptor on CD4+ T cells from 
human immunodeficiency virus (HIV)-1-infected patients. The objective of this study was 
to investigate the expression of CD300a on CD4+ T cells from HIV-infected patients on 
suppressive combined antiretroviral therapy (cART) and cART naïve patients. Our results 
have demonstrated that the expression levels of this inhibitory receptor were higher on 
CD4+ T cells from HIV-1 infected subjects compared with healthy donors, and that cART 
did not reverse the altered expression of CD300a receptor in these patients. We have 
observed an increase of CD300a expression on both PD1+CD4+ and CD38+CD4+ 
T cells from HIV-1 infected people. Interestingly, a triple positive (CD300a+PD1+CD38+) 
subset was expanded in naïve HIV-1 infected patients, while it was very rare in healthy 
donors and patients on cART. Finally, we found a negative correlation of CD300a 
expression on CD4+ T lymphocytes and some markers associated with HIV-1 disease 
progression. Thus, our results show that HIV-1 infection has an impact in the regulation 
of CD300a inhibitory receptor expression levels, and further studies will shed light into the 
role of this cell surface receptor in the pathogenesis of HIV infection.
Keywords: cD300, cD300a, human immunodeficiency virus-1, cD4 T cells, PD1
inTrODUcTiOn
In order to mount an adequate and effective response against offenses, the immune system is 
orchestrated in part by a balance between stimulatory and inhibitory signals transmitted by a variety 
of receptors found on the surface of immune cells. Human CD300a is a member of the CD300 
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receptor family whose genes are located on chromosome 17 (1, 2). 
CD300a is a type I transmembrane protein formed by an immu-
noglobulin (Ig)V-like extracellular domain, a transmembrane 
region, and a long cytoplasmic tail containing three classical and 
one non-classical immunoreceptor tyrosine-based inhibitory 
motifs, which provides the receptor with an inhibitory capacity 
(1–5). Regarding to the ligands, CD300a is known to recognize 
phosphatidylserine (PS) and phosphatidylethanolamine (PE), 
phospholipids that are found in the inner leaflet of plasma mem-
brane in resting cells and are exposed to the outer leaflet when 
cells get activated, transformed, infected, or dead (6–8).
Human CD300a receptor is found on the surface of both mye-
loid and lymphoid cells. Within human CD4+ T lymphocytes, it 
is differentially expressed among different subsets, and newborns 
CD4+ T cells significantly express lower levels of this receptor 
than adults (9, 10). Human Th1 cells expressing CD300a tend to 
be polyfunctional and after stimulation express the transcription 
factor eomesodermin (Eomes) (9). CD300a inhibitory receptor 
has the capacity to modulate CD4+ T cell responses through a 
signaling pathway that involves the src homology 2 domain con-
taining protein tyrosine phosphatase (SHP)-1 (3, 11). Specifically, 
the co-ligation of the T cell receptor (TCR) and CD300a inhibited 
the calcium mobilization evoked by TCR alone and modulated 
the interferon (IFN)γ production on Th1 polarized cells (11). 
Importantly, over the past few years, several publications have 
emphasized the significant role that CD300a has in complex bio-
logical processes such as cytokine production and phagocytosis, 
and in a diversity of diseases including autoimmune disorders, 
allergic and inflammatory diseases, hematological malignancies, 
viral infections, etc. (2, 12–15).
Several studies have described the role of CD300a and its 
ligands PS and PE in the mechanisms that viruses use to enter 
host cells and also to evade the attack of the immune system. 
It is well known that one of the strategies used by viruses is 
apoptotic mimicry. Through this mechanism, which consists 
of enclosing viruses in a lipid bilayer obtained from the plasma 
membrane of host cells, they impersonate apoptotic cells and 
debris by concentrating PS and PE within their membranes, as 
it is the case of enveloped viruses; or by covering themselves 
in cell-derived PS and PE-containing vesicles, as it happens for 
many non-enveloped viruses (16–18). In this context, it has been 
shown that the interaction of CD300a with PS and PE enhances 
the infection of Dengue virus and other mosquito-borne viruses 
such as Yellow fever, West Nile, and Chikungunya viruses (14). 
In addition, Grauwet et al. have described that the US3 protein 
kinase of pseudorabies virus induces the exposure of PS and PE 
on the infected cells, a process that depends on the kinase activity 
of US3 and on group I p21-activated kinases. In consequence, the 
binding of CD300a on NK cells to the infected cells is increased, 
leading to an inhibition of NK cell-mediated killing (15). As a 
matter of fact, NK cells express high levels of CD300a (4, 5, 8, 10).
There are few reports describing the potential implication of 
CD300a during human immunodeficiency virus (HIV) infec-
tion. In a first study, a positive correlation between the mRNA 
levels of CD300a and the levels of basic leucine zipper transcrip-
tion factor ATF-like (BATF) was described on HIV-specific 
CD8+ T  cells. PD1, a marker of exhausted T  cells, inhibits 
their function by upregulating BAFT, which has been suggested 
to increase other negative feedback pathways, including the 
expression of the CD300a inhibitory receptor, indicating that 
this molecule could also have a role in T cell exhaustion during 
HIV infection (19). Other report described a downregulation 
of CD300a expression on B cells from HIV-infected individu-
als, which could explain in part the B cell hyper-activation and 
dysfunction found in these patients (20). The downregulation 
in CD300a expression on B  cell subsets was not corrected by 
effective antiretroviral therapy. On the other hand, a correlation 
between CD4+ T cell count and CD300a expression on memory 
B cells was observed in patients whose viremia was controlled by 
combined antiretroviral therapy (cART) (20). Finally, we have 
recently described the expression of CD300 receptors on mono-
cytes from chronically HIV-1 infected patients under cART and 
its association with monocyte cytokine production. However, 
regarding to CD300a expression on monocytes, no differences 
were found between healthy donors and cART-treated HIV-1-
infected patients (21).
In terms of CD4+ T cells, the expression of the CD300a recep-
tor in HIV-infected patients and its regulation is still unknown. 
In this study, we have found that the cell surface levels of this 
inhibitory receptor are increased on CD4+ T cells after HIV-1 
infection and it is not reverted by cART. Interestingly, a triple 
positive (CD300a+PD1+CD38+) subset was expanded in cART 
naïve HIV-1 infected patients, while it was very rare in healthy 
donors and cART-treated patients. We have also found an asso-
ciation between CD300a expression on CD4+ T lymphocytes and 
HIV disease progression markers.
MaTerials anD MeThODs
subjects and samples
In this work, frozen peripheral blood mononuclear cells (PBMCs) 
from healthy adult donors and chronically HIV-1 infected patients 
were analyzed. Blood samples from healthy donors (n = 19) were 
obtained from the Basque Biobank for Research (http://www.
biobancovasco.org). All subjects provided written and signed 
informed consent in accordance with the Declaration of Helsinki. 
The study was approved by the Basque Ethics Committee for 
Clinical Research (PI2014017 and PI2013108). Plasma and PBMC 
cryopreserved samples from asymptomatic HIV-1 infected 
patients on suppressive cART (viral load < 20 copies/mL) for at 
least 6  months (n =  16) and from cART naïve HIV-1 infected 
subjects (viral load > 9,300 copies/mL) (n = 20), were collected 
from the Virgen del Rocío University Hospital in Seville (Spain). 
Clinical data of cART-treated and cART naïve HIV-1 infected 
patients are described in Tables S1 and S2 in Supplementary 
Material, respectively. All patients provided written and signed 
informed consent in accordance with the Declaration of Helsinki. 
The study was approved by the Virgen del Rocío University 
Hospital Ethics Committee for Research (15/2009).
laboratory Methods
CD4 T-cell counts were determined in fresh whole blood using 
an Epic XL-MCL flow cytometer (Beckman-Coulter, Brea, CA, 
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USA) according to the manufacturer’s instructions. Plasma HIV-1 
RNA concentration was measured using quantitative polymerase 
chain reaction (COBAS Ampliprep/COBAS Taqman HIV-1 test, 
Roche Molecular Systems, Basel, Switzerland) according to the 
manufacturer’s protocol. The detection limit for this assay was 20 
HIV RNA copies per milliliter.
High-sensitive C-reactive protein (hsCRP) and β2-microglobulin 
were determined with an immunoturbidimetric assay using 
COBAS 701 (Roche Diagnostics, GmbH, Mannheim, Germany). 
d-dimer levels were determined using an automated latex enhan-
ced immunoassay (HemosIL, d-Dimer HS 500, Instrumentation 
Laboratory) in plasma samples stored at −20°C.
Flow cytometry analysis
To perform flow cytometry-based procedures, the following 
fluorochrome-conjugated monoclonal mouse anti-human anti-
bodies were used: PerCP-Cy5.5 anti-PD1 (clone EH12.1), 
PE-Cy7 anti-CD3 (clone SK7), APC anti-CD38 (clone HIT2) 
and BV421 anti-CD4 (clone RPA-T4) from BD Biosciences; PE 
anti-CD300a (clone E59.126) from Beckman Coulter; APC-
eFluor780 anti-CD27 (clone O323) from eBioscience and BV510 
anti-CD45RA (clone HI100) from BioLegend. Frozen PBMCs 
were thawed at 37°C and washed with PBS two times. Afterward, 
cells were stained with LIVE/DEAD Fixable Near-IR Dead Cell 
Stain Kit (Life Technologies) to test for viability, followed by a 
second step of incubation with different fluorochrome-conju-
gated antibodies to assess the expression of surface markers. In 
both steps, PBMCs were incubated for 30 min on ice protected 
from the light and were washed twice with 2.5% of bovine serum 
albumin in PBS. Finally, cells were fixed with 200 µl of 4% of 
paraformaldehyde (Sigma-Aldrich) for 15 min at 4°C and then 
other 200 µl of PBS were added. Samples were acquired with a 
flow cytometer FACS Canto II (BD Biosciences), using the FACS 
Diva software (BD Biosciences). Data were analyzed with FlowJo 
10.0.7 software.
enzyme-linked immunosorbent assay 
(elisa)
Enzyme-Linked Immunosorbent Assays were performed to 
measure soluble markers in the plasma samples from HIV-1-
infected patients: sCD163 (Macro163™, IQ Products) and sCD14 
(Human CD14 ELISA Kit, Diaclone Immunology Products) 
levels were determined. ELISA experiments were performed 
following the manufacturers’ protocol.
Data representation and statistical 
analysis
GraphPad Prism software (version 6.01) was employed for the 
graphical representation and statistical analysis. Data were 
represented in scatter dot plots with the median or bar graphs 
showing the mean with SEM. Prior to statistical analyses, data 
were tested for normal distribution with D’Agostino and Pearson 
normality test. Then, parametric tests were applied when the 
normality test was passed, while non-parametric tests were 
utilized when it was not. Differences between healthy donors and 
naïve and cART-treated HIV-1 infected patients were evaluated 
with the non-parametric unpaired Mann–Whitney test, and the 
comparisons within cell subsets from each subject were made 
with the non-parametric Wilcoxon matched-pairs test. The same 
software was used to carry out correlation analysis. In this case, 
parametric Pearson correlation test or non-parametric Spearman 
test was employed depending on data distribution. Boolean gate 
analysis were done utilizing the FlowJo 10.0.7 software and data 
were represented in pie chart graphs using SPICE v5.3 software 
and bar graphs showing the mean with SEM utilizing GraphPad 
Prism software.
resUlTs
cD300a expression on cD4+  
T lymphocytes From hiV-infected  
Patients
The human CD300a inhibitory receptor is known to be dif-
ferentially expressed on CD4+ T  cell subpopulations (9–11). 
Here, we have analyzed the CD300a expression levels on CD4+ 
T cell subsets from HIV-1 infected patients in comparison with 
healthy donors. CD27 and CD45RA cell surface receptors were 
used as markers to identify different CD4+ T subpopulations: 
naïve (CD27+CD45RA+), memory (CD27+CD45RA−), effec-
tor/memory (CD27−CD45RA−), and terminal differentiated 
effector/memory (TEM) (CD27−CD45RA+) cells (Figure 
S1A in Supplementary Material). In agreement with previous 
publications, the frequency of each subset varied between the 
different groups of patients (Figure S1B in Supplementary 
Material) (22–24). First, we examined the expression of CD300a 
on CD4+ T cell subsets from healthy donors, cART naïve, and 
patients on cART. Similar to other published findings (10), we 
have found that in healthy donors, naïve CD4+ T cells exhibited 
the lowest CD300a expression levels while TEM cells displayed 
the highest. Naïve cells were negative or expressed low levels of 
CD300a and almost all TEM cells were positive and expressed 
high levels of CD300a (Figure 1A). On the other hand, memory 
and effector/memory CD4+ T  cells are divided into two well 
defined CD300a+ and CD300a− subpopulations (Figure  1A). 
Regarding CD4+ T  cells from HIV-1 infected patients, we 
observed a similar CD300a expression pattern among the four 
subpopulations (Figure 1A).
Next, we compared the percentage of CD300a+ cells on CD4+ 
T cells from healthy donors with the cells from cART naïve and 
cART-treated HIV-1 infected patients. In general, the results 
did not show significant differences between groups (Figure 
S2 in Supplementary Material). In addition, we also checked 
the median fluorescence intensity (MFI) of CD300a within the 
CD300a+ cells in the same CD4+ T  cell subpopulations, as a 
measure of the amount of CD300a molecules on the surface of 
CD300a+ cells. We observed a significant upregulation of CD300a 
expression on CD4+ T cells from HIV-1-infected patients when 
compared with cells from healthy donors. This was observed in 
every CD4+ T cell subset, with the exception of TEM cells, which 
only exhibited significant differences between healthy donors 
and cART-treated patients (Figure  1B). Therefore, our results 
demonstrated that HIV-1 infection increases CD300a expression 
FigUre 1 | CD300a inhibitory receptor expression on CD4+ T cell subsets from healthy donors and human immunodeficiency virus (HIV)-1 infected patients. (a) 
Representative histograms showing the percentage of CD300a+ cells and the median fluorescence intensity (MFI) of CD300a within positive cells on CD4+ T cell 
subpopulations. Data from a representative healthy donor, a cART naïve (HIV) and a patient on cART (HIV ART) are shown. (B) Dot plots showing the MFI of CD300a 
within positive cells on CD4+ T cell subsets from healthy donors and cART naïve (HIV) and cART-treated (HIV ART) HIV-1-infected patients. Each dot represents a 
subject and the median is shown. *p < 0.05, **p < 0.01.
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levels on CD4+CD300a+ cells and that cART does not reverse 
the upregulation of CD300a expression found in these patients.
cD300a expression on PD1+cD4+ T cells
During chronic HIV-1 infection, the persistent antigen expo-
sure gives rise to T  cell exhaustion, which is characterized by 
a reversible loss of effector functions and proliferative capacity. 
Exhausted T  cells are characterized by a higher expression of 
inhibitory receptors such as PD1, TIM-3, and LAG-3 (25, 26). 
The PD1 inhibitory receptor, inductively expressed on T  cells 
upon activation, has been identified as a major regulator of 
T  cell exhaustion during chronic HIV infection (19, 27, 28). 
We decided to measure the expression of CD300a receptor 
on PD1+CD4+ T  lymphocytes from HIV-1 infected patients. 
First, we were able to reproduce the results obtained in previous 
works (22, 24), since we observed an increase in the percentage 
of PD1+ cells on memory, effector/memory and TEM CD4+ 
T cells from HIV-viremic patients that are not receiving cART 
(Figure S3 in Supplementary Material). The frequency of PD1+ 
cells was significantly diminished with cART on the same CD4+ 
T  cell subsets from HIV-1-infected patients (Figure S3A in 
Supplementary Material).
Afterward, we analyzed the percentage of CD300a+ cells 
within PD1+ and PD1− CD4+ T  lymphocytes from healthy 
donors, cART naïve, and cART-treated HIV-1 infected patients 
(Figure S3B in Supplementary Material). Specifically, we focused 
on memory, effector/memory and TEM CD4+ T  cells. Naïve 
CD4+ T  cells were not analyzed since they express negligible 
levels of PD1, as we (Figure S3A in Supplementary Material) and 
others have shown (24, 29). Regarding to effector/memory and 
TEM CD4+ T cell subsets we saw that PD1+ cells exhibited a 
higher percentage of CD300a+ cells than PD1− cells, in both 
healthy donors and HIV-1 infected patients with the exception 
of TEM cells from cART-treated patients, which did not display 
FigUre 2 | CD300a expression on PD1+CD4+ T lymphocytes. Bar graphs showing the percentage of CD300a+ cells (a) and the median fluorescence intensity 
(MFI) of CD300a within positive cells (B) in PD1+CD4+ and PD1-CD4+ T lymphocytes from healthy donors, cART naïve [human immunodeficiency virus (HIV)] and 
patients on cART (HIV ART). Error bars represent the SEM. (c) Dot plots representing the MFI of CD300a within CD4+ T cells expressing both CD300a and PD1 
from healthy donors, cART naïve (HIV) and cART-treated (HIV ART) HIV-1 infected patients. Each dot represents a subject and the median is shown. *p < 0.05, 
**p < 0.01, ***p < 0.001, ****p < 0.0001.
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any difference between PD1+ and PD1− cells (Figure 2A). On 
the other hand, the frequency of CD300a+ cells in the PD1+ and 
PD1− memory CD4+ T  lymphocytes were somehow different 
between the groups of patients (Figure 2A). Importantly, when 
we measured the MFI of the CD300a on PD1+CD300a+ and 
PD1−CD300a+ cells, we observed that PD1+ cells in all CD4+ 
T  cell subsets always exhibited higher levels of expression of 
CD300a than PD1− cells (Figure 2B).
Finally, we compared the MFI of CD300a on PD1+CD300a+ 
cells from healthy donors with the cells from HIV-1 infected 
patients. We observed that PD1+ cells from both cART naïve 
and cART-treated HIV-1-infected patients displayed a higher 
MFI of CD300a than cells from healthy donors (Figure 2C). 
Altogether, these results indicate that HIV-1 infection induces 
an increase on the expression of CD300a inhibitory receptor 
on CD4+ T  cells that otherwise already express the check-
point PD-1.
cD300a expression on cD38+cD4+  
T cells
Human immunodeficiency virus-1 infection induces T  cell 
(CD4+ and CD8+) dysfunction and activation, which conse-
quently upregulates the expression of the surface receptor CD38 
on these cells. In fact, high expression of CD38 on T lymphocytes 
FigUre 3 | CD300a expression on CD38+CD4+ T lymphocytes. (a) Bar graphs representing the percentage of CD300a+ cells within CD38+CD4+ and 
CD38−CD4+ T lymphocytes from healthy donors, cART naïve [human immunodeficiency virus (HIV)] and patients on cART (HIV ART). Error bars represent the SEM. 
(B) Dot plots representing the median fluorescence intensity of CD300a within CD4+ T cells expressing both CD300a and CD38 from healthy donors, cART naïve 
(HIV), and patients on cART (HIV ART). Each dot represents a subject and the median is shown. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
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is known to predict HIV infection progression (30–32). Therefore, 
we decided to utilize the marker CD38 in order to investigate the 
expression of CD300a receptor on activated CD4+ T cells from 
HIV-1 infected people. In agreement with previous publications 
(30, 33), we observed that, except for the naïve subset, all CD4+ 
T cells from cART naïve HIV-1 infected patients express higher 
percentages of CD38+ cells than the cells from healthy donors or 
cART-treated patients (Figure S4A in Supplementary Material). 
There were no significant differences in the frequency of CD38+ 
cells on naïve CD4+ T cells from healthy subjects and infected 
patients (Figure S4A in Supplementary Material). In fact, resting 
naïve CD4+ T  cells express constitutively low levels (MFI) of 
CD38, making this receptor a proper activation marker only for 
T  cells with a non-naïve phenotype (30). Hence, naïve CD4+ 
T cells were not considered in the following analysis.
We determined the percentage of CD300a+ cells on 
CD38+CD4+ T  lymphocytes, focusing on memory, effector/
memory, and TEM CD4+ T cells, from both healthy donors and 
infected patients (Figure S4B in Supplementary Material). In all 
subjects, memory and effector/memory CD4+ T cells expressing 
CD38 exhibited a lower percentage of CD300a+ cells than CD38− 
cells (Figure 3A). The same result was obtained from TEM cells 
FigUre 4 | Co-expression of CD300a, PD1, and CD38 on CD4+ T cells. Boolean gate analysis showing the frequency of memory, effector/memory, and TEM 
CD4+ T cells expressing CD300a, PD1, and CD38, in healthy donors, cART naïve [human immunodeficiency virus (HIV)], and patients on cART (HIV ART). Data are 
represented in pie chart graphs and bar graphs showing the mean with SEM. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
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but only in cART naïve patients (Figure 3A). Importantly, when 
we compared the MFI of CD300a on CD38+CD300a+ cells from 
healthy donors with the cells from cART naïve and cART-treated 
patients, we saw a higher expression of the CD300a receptor on 
memory and effector/memory CD4+ T cells from HIV-1-infected 
patients (Figure 3B).
We finally carried out a Boolean gate analysis, in order to 
compare the co-expression of CD300a, PD1, and CD38 receptors 
on non-naïve CD4+ T cells from healthy donors and cART naïve 
and cART-treated HIV-1 infected patients. Regarding memory 
and effector/memory CD4+ T  lymphocytes, we saw a higher 
percentage of triple positive (CD300a+PD1+CD38+) and dou-
ble positive (CD300a+PD1+CD38−, CD300a+PD1−CD38+ 
and CD300a−PD1+CD38+) cells in cART naïve patients than in 
healthy donors or cART-treated patients. The percentage of triple 
negative cells (CD300a−PD1−CD38−) was lower in cART naïve 
patients. TEM CD4+ T cells displayed similar results, mainly in 
the frequency of triple-positive cells (Figure 4). Altogether, we 
observed that in terms of CD300a, PD1, and CD38 expression, 
CD4+ T  cells from healthy donors and cART-treated patients 
were very similar, while the CD4+ cells from cART naïve HIV-1 
infected patients exhibited a clearly different phenotype with 
a very interesting appearance of a significant triple positive 
(CD300a+PD1+CD38+) cell subset (Figure 4).
association of cD300a expression With 
Markers of hiV-1 infection Progression
Once we have described that CD300a expression is upregulated 
on CD4+ T  lymphocytes from HIV-1 infected patients, we 
investigated if these findings could have any clinical relevance 
to determine HIV-1 disease progression. To do that, cor-
relation analysis were carried out between CD300a expression 
and markers that are currently used for clinical monitoring of 
HIV-1 infected patients, including viral load and CD4+ T  cell 
count, and also several soluble markers from plasma such as 
β2-microglobulin, d-dimer, hsCRP, soluble CD163 (sCD163), 
FigUre 5 | Association of CD300a expression on CD4+ T lymphocytes with markers of human immunodeficiency virus (HIV)-1 infection progression in cART naïve 
HIV-1 infected patients. Correlation analysis of the percentage of CD300a+ cells on naïve (left column), memory (middle column), and effector/memory (right column) 
CD4+ T lymphocytes, with CD4+ T cell counts and β2-microglobulin (B2M), high sensitive C-reactive protein (hsCRP), and soluble CD14 (sCD14) levels in cART 
naïve HIV-1 infected patients. *p < 0.05, **p < 0.01.
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and soluble CD14 (sCD14). Figure S5 in Supplementary Material 
shows the values of each soluble marker and CD4+ T cell counts 
in both cohorts of patients. As expected, HIV-1-infected patients 
under cART exhibited a higher CD4+ T  cell count than non-
treated patients. In addition, cART-treated patients had lower 
serum levels of β2-microglobulin and sCD163 than cART naïve 
patients (Figure S5 in Supplementary Material). No correlation 
was found between the percentage of CD300a+ cells and viral 
load or d-dimer and sCD163 levels (data not shown). On the 
other hand, we did observe a significant correlation between 
CD4+ T cell counts, β2-microglobulin, hsCRP, and sCD14 levels 
and the frequency of CD300a+ cells in untreated HIV-1 infected 
patients. The percentage of CD300a+ cells within memory CD4+ 
T lymphocytes was positively associated with CD4+ T cell count, 
while it was negatively correlated with β2-microglobulin and 
hsCRP levels (Figure  5). Moreover, naïve CD4+ T  cells from 
cART naïve patients also exhibited a negative association between 
the percentage of CD300a+ cells and sCD14 plasma levels, and 
the same tendency was observed on memory CD4+ T  cells 
(Figure  5). In contrast, related to the effector/memory CD4+ 
T cells, we observed a somehow contradictory correlation pattern 
of the frequency of CD300a+ cells with the progression markers, 
FigUre 6 | Association of CD300a expression on CD4+ T lymphocytes with markers of human immunodeficiency virus (HIV)-1 infection progression in HIV-1 
infected patients on cART. Correlation analysis of the percentage of CD300a+ cells on naïve (left column), memory (middle column), and effector/memory (right 
column) CD4+ T lymphocytes, with CD4+ T cell counts and β2-microglobulin (B2M), high sensitive C-reactive protein (hsCRP), and soluble CD14 (sCD14) levels in 
HIV-1-infected patients on cART. *p < 0.05.
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as for example, the positive correlation between the percentage 
of CD300a+ cells and sCD14 levels (Figure 5), making it difficult 
to obtain a clear interpretation of the results in this CD4+ T cell 
subset from untreated patients.
Interestingly, and in opposition to the analyses performed 
with samples from untreated patients, regarding naïve or memory 
CD4+ T  cells from cART-treated patients, we did not see any 
correlation between the studied parameters, but an opposite 
tendency was noticed (Figure 6). Furthermore, effector/memory 
cells from HIV ART displayed a significant negative correlation 
between the percentage of CD300a+ cells and CD4+ T  cell 
numbers (Figure  6). TEM CD4+ T  cells from both untreated 
and cART-treated HIV-1 infected patients did not show any sig-
nificant correlation (data not shown) with the CD4+ T cell count 
and serum levels of soluble markers. Altogether, these results 
suggest that a higher frequency of CD300a+ cells on CD4+ 
T cells could be associated to a better progression in cART naïve 
HIV-1-infected people, while this association disappears after the 
introduction of cART.
DiscUssiOn
The ability of the CD300a inhibitory receptor to modulate immune 
cell effector functions and its involvement in the pathogenesis 
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of several diseases has recently triggered a great interest in this 
molecule (1, 2, 12, 13). The CD300a receptor is known to have an 
important role in various viral infections, enhancing viral entry 
and promoting viral escape from the immune system (14, 15, 
34). However, there are only a few publications about CD300a 
on HIV-1 infection. These publications indicate a possible role 
for CD300a in the exhaustion of HIV-specific CD8+ T  cells 
(19) and in the B cell hyper-activation and dysfunction found 
in HIV-1 infected patients (20). In this work, we report that the 
expression levels of the CD300a inhibitory receptor are increased 
on CD4+ T  cells from HIV-1-infected patients. Moreover, we 
found a CD4+ T cell population co-expressing PD1, CD38, and 
CD300a that is expanded in cART naïve HIV-1 infected patients, 
while in healthy donors and cART-treated patients is rare. We 
also discovered an association of CD300a expression with some 
markers of disease progression in non-treated HIV-1-infected 
patients.
The differential expression of CD300a inhibitory receptor 
among CD4+ T  cell subpopulations was previously described 
in healthy donors (9–11). Here, we first observed that the 
expression pattern in the CD4+ T cell subsets in HIV-1 infected 
patients was similar to the one exhibited by healthy donors: 
naïve CD4+ T cells displayed the lowest levels of CD300a while 
TEM cells the highest and memory and effector/memory CD4+ 
T cells expressed intermediate levels. But importantly, we have 
discovered that the expression levels of the CD300a receptor in 
HIV-1 infected patients were significantly altered when we com-
pared them with the expression on CD4+ T cells from healthy 
donors. Hassouneh et  al. have described a higher percentage 
of CD300a+ cells on total CD4+ T  cells in healthy donors, 
mainly in middle-age and old people, which are seropositive 
for cytomegalovirus (CMV) (35). Published data have shown 
that there is a high incidence of CMV positive blood donors in 
Spain (36) and also of CMV positive organ donors (see report 
from the Spanish National Transplant Organization at www.
ont.es/infesp/Memorias/Memoria%20Donación%202017.pdf). 
On the other hand, it is also well known that a high percentage 
of HIV-1 infected people are co-infected with CMV (50–80%) 
(37, 38). Our results showed no significant differences in the 
frequency of CD300a+ cells on total CD4+ T cells and in the dif-
ferent cell subsets (Figure S2 in Supplementary Material), which 
somehow could be explained by the high incidence of CMV 
in both healthy donors and HIV-1-infected patients. On the 
other hand, we observed a significant upregulation of CD300a 
MFI on CD4+CD300a+ T  cells from HIV-1-infected patients 
(Figure 1). Future studies are required to determine the role of 
CMV infection on the altered expression of CD300a observed in 
HIV-1-infected patients.
The expression of CD300a molecule is regulated by different 
stimuli. For instance, CD300a expression is upregulated after 
TLR9 stimulation on memory B  cells (20) and its expression 
also increases on monocytes stimulated with IFNγ and cultured 
under hypoxia conditions (39, 40). The reason of why the CD300a 
receptor is upregulated on HIV-1-infected CD4+ T cells is still 
unknown. Though, as other immunomodulatory receptors such 
as PD1, the CD300a inhibitory receptor may be inductively 
expressed after T cell activation as a regulatory mechanism during 
HIV-1 infection, and probably the cytokine environment has an 
important role determining the expression levels of CD300a. It 
has been previously published that Th1 polarization in the pres-
ence of IL-12 induces the generation of mostly CD300a+ cells in 
healthy donors (9). Moreover, patients with HIV infection display 
an increased IL-12 production in vivo and ex vivo (41). Thus, it 
could be possible that the higher IL-12 production, among others, 
during acute/early HIV infection, may induce the upregulation 
of CD300a and this overexpression might be maintained during 
chronic HIV infection. Clearly, more studies are required to 
investigate the factors leading to an increase in the expression 
levels of CD300a during HIV infection. On other hand, our 
results did not show significant differences in CD300a expression 
levels on CD4+ T cells between cART naïve and cART-treated 
HIV-1 infected people, meaning that cART does not reverse 
the upregulation of CD300a found in infected patients. This is 
in line with previous results published by us where the altered 
levels of CD300a expression on B cells are not reversed by cART 
(20). The maintenance of the higher expression levels of CD300a 
inhibitory receptor in cART-treated HIV-1-infected subjects 
could be a reflection of the continuous immune activation in 
these patients, even after cART. It is well known that although 
cART decreases viral load to undetectable levels, as HIV is not 
completely eradicated, the activation of the immune system still 
occurs (32, 42–45).
Consistent with the results described by Quigley et al., who 
showed a positive correlation between CD300a mRNA levels and 
BATF, a transcription factor downstream of PD1 that increases 
inhibitory pathways on HIV-specific exhausted CD8+ T  cells 
(19), here, we have discovered a higher frequency of CD300a+ 
cells on PD1+ cells in comparison with PD1− cells within most of 
CD4+ T cell subsets from both healthy donors and HIV-1 infected 
patients. It is well known that PD1 is an inhibitory receptor that is 
upregulated after T cell activation as a negative feedback mecha-
nism (27–29). Several publications have proposed that PD1, apart 
from inducing immune exhaustion, identify a particular T cell 
differentiation stage and effector function (46–48). For instance, 
memory PD1+CD4+ T  lymphocytes from healthy donors and 
HIV-1 infected children preferentially secreted IFNγ and IL-17A 
(49). Previously, it has been described that in healthy donors, 
CD4+ T cells expressing CD300a were higher producers of IFNγ 
than CD300a− cells, and that they were more polyfunctional (9, 
11). Therefore, CD300a receptor, as PD1, may represent a CD4+ 
T cell subset with specific effector functions, at least in healthy 
donors. But even more relevant for this study, the expression lev-
els of the CD300a inhibitory receptor were significantly higher on 
PD1+CD4+ T lymphocytes from HIV-1-infected patients when 
compared with the same cells from healthy donors.
It is well known that HIV-1 induces T  cell activation and 
consequently increases the expression of CD38 (30, 50). A higher 
CD38 expression on CD4+ T cells from viremic HIV-1-infected 
people is a biomarker of poor prognosis and is strongly associ-
ated with short survival in patients with advanced infection 
(30–32, 51). In this study, we saw a decrease in the percentage of 
CD300a+ cells within CD38+CD4+ T  lymphocytes from both 
healthy people and HIV-1 infected patients, in comparison with 
CD38−CD4+ T cells. But importantly, CD38+ cells from HIV-1 
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infected patients exhibited higher expression levels of CD300a 
than the CD38+ cells from healthy donors, which is consistent 
with a general upregulation of CD300a expression levels on 
different CD4+ T cell populations after HIV-1 infection, regard-
less of the exhaustion or activation status of the cells. Finally, 
Boolean gate analysis showed that in terms of CD300a, PD1, 
and CD38 expression pattern, the phenotype of CD4+ T  cells 
from healthy donors was very similar to the one of cART-treated 
HIV-1 infected people, while naïve patients for cART exhibited 
a different pattern. It is very possible that the differences found 
between cART-treated and non-treated HIV-1 infected subjects 
are mainly due to their disparities in PD1 and CD38 expression. 
Of note, these analyses revealed an expansion of a triple positive 
cell subset (CD300a+PD1+CD38+) in untreated patients that is 
very rare in healthy donors and HIV-1 patients on cART. The 
increased percentage of this triple positive population is very pos-
sibly the consequence of an increase in PD1+ and CD38+ cells 
in cART naïve patients rather than an increase in the frequency 
of CD300a+ cells. This subset may represent a highly activated 
population characterized by high expression of immune check-
points. In the future, it will be very interesting to study in depth 
this subpopulation, both phenotypically (immune checkpoints) 
and functionally (proliferation, cytokine production, etc.).
Finally, we investigated if there was any association between 
CD300a expression and markers of HIV-1 disease progression. 
An increase in CD4+ T cell counts has been broadly interpreted 
as good prognosis in HIV-1-infected people (31, 52). Moreover, 
there are various soluble molecules that have been related to HIV-1 
infection progression. Among others, high β2-microglobulin and 
hsCRP values in plasma reflect the activation of immune system 
(53, 54) and illustrate disease progression (54, 55). Furthermore, 
high plasma levels of sCD14, a marker of microbial translocation, 
have also been related to disease progression and poor response 
to cART in HIV-infected patients (56–58). Our results showed 
that in untreated HIV-1-infected patients, the percentage of cells 
expressing CD300a was positively correlated with CD4+ T cell 
numbers, while was negatively associated to β2-microglobulin, 
hsCRP, and sCD14 levels, suggesting that a higher frequency of 
CD300a+ cells could be indicative of good prognosis in active 
HIV-1 infection. In contrast, our results did not show the same 
tendency regarding to CD4+ T cells from HIV-infected patients 
receiving cART. In fact, an opposite pattern between naïve cART 
and treated patients was found. This could suggest that this recep-
tor might play different roles depending on the levels of virus 
replication and T cell activation. Since T cell activation supports 
viral replication, in untreated HIV-1 patients, a higher expression 
of the CD300a inhibitory receptor might be beneficial. However 
in patients under effective cART, because viral levels decrease 
and consequently permit the antiviral effects to prevail, higher 
expression levels of CD300a inhibitory receptor could be coun-
terproductive for T cell activation. Undoubtedly, further studies 
are required to test this hypothesis.
In summary, our study demonstrates that chronically HIV-1 
infected patients exhibit an altered expression of CD300a inhibi-
tory receptor on CD4+ T  lymphocytes that is not reverted by 
effective cART. Moreover, we have discovered a negative cor-
relation between CD300a levels and some markers of HIV-1 
infection progression in cART naïve HIV-1 infected patients. 
These are promising findings that will lead to new research aimed 
at further understanding the role of the CD300a inhibitory recep-
tor in CD4+ T lymphocytes during chronic HIV-1 infection.
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